KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for TherapeuticsMD (TXMD) over the last 4 years, with Q3 2025 value amounting to $11.6 million.

  • TherapeuticsMD's Shares Outstanding (Diluted Average) rose 36.42% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 36.42%. This contributed to the annual value of $11532.0 for FY2024, which is 1044.92% up from last year.
  • As of Q3 2025, TherapeuticsMD's Shares Outstanding (Diluted Average) stood at $11.6 million, which was up 36.42% from $11.6 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Shares Outstanding (Diluted Average) registered a high of $11.6 million during Q2 2025, and its lowest value of $10441.0 during Q4 2023.
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $10.2 million (2023), whereas its average is $9.1 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first crashed by 9988.85% in 2023, then surged by 1822.84% in 2024.
  • TherapeuticsMD's Shares Outstanding (Diluted Average) (Quarter) stood at $9.4 million in 2022, then crashed by 99.89% to $10441.0 in 2023, then grew by 10.45% to $11532.0 in 2024, then skyrocketed by 100264.2% to $11.6 million in 2025.
  • Its last three reported values are $11.6 million in Q3 2025, $11.6 million for Q2 2025, and $11.6 million during Q1 2025.